{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:08:33Z","timestamp":1789013313888,"version":"build-2803163510"},"reference-count":78,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.yebeh.2026.111192","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T19:50:20Z","timestamp":1784145020000},"page":"111192","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Optimizing epilepsy management and pregnancy outcomes: the role of therapeutic drug monitoring"],"prefix":"10.1016","volume":"184","author":[{"given":"Abrar","family":"Al-Faraj","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Souzana","family":"Obretenova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trudy D.","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5216-2018","authenticated-orcid":false,"given":"P.Emanuela","family":"Voinescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.yebeh.2026.111192_b0005","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1684\/epd.2019.1105","article-title":"Management of epilepsy in pregnancy: a report from the international league against epilepsy task force on women and pregnancy","volume":"21","author":"Tomson","year":"2019","journal-title":"Epileptic Disord"},{"issue":"4","key":"10.1016\/j.yebeh.2026.111192_b0010","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s13669-022-00344-5","article-title":"Epilepsy complicating pregnancy","volume":"11","author":"Voinescu","year":"2022","journal-title":"Curr Obstet Gynecol Rep"},{"issue":"11","key":"10.1016\/j.yebeh.2026.111192_b0015","doi-asserted-by":"crossref","first-page":"e1002160","DOI":"10.1371\/journal.pmed.1002160","article-title":"Pregnancy-associated changes in pharmacokinetics: a systematic review","volume":"13","author":"Pariente","year":"2016","journal-title":"PLoS Med"},{"key":"10.1016\/j.yebeh.2026.111192_b0020","first-page":"5","article-title":"Physiologic and pharmacokinetic changes in pregnancy","volume":"3","author":"Costantine","year":"2014","journal-title":"Front Pharmacol"},{"issue":"13","key":"10.1016\/j.yebeh.2026.111192_b0025","doi-asserted-by":"crossref","first-page":"e1228","DOI":"10.1212\/WNL.0000000000006240","article-title":"Antiepileptic drug clearances during pregnancy and clinical implications for women with epilepsy","volume":"91","author":"Voinescu","year":"2018","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.yebeh.2026.111192_b0030","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.yebeh.2013.06.026","article-title":"Antiepileptic drug clearance and seizure frequency during pregnancy in women with epilepsy","volume":"29","author":"Reisinger","year":"2013","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2026.111192_b0035","doi-asserted-by":"crossref","unstructured":"Pennell PB, Peng L, Newport DJ, et al. Lamotrigine in pregnancy. Neurology. 2008;70(22_part_2):2130-2136. doi:10.1212\/01.wnl.0000289511.20864.2a.","DOI":"10.1212\/01.wnl.0000289511.20864.2a"},{"issue":"4","key":"10.1016\/j.yebeh.2026.111192_b0040","doi-asserted-by":"crossref","DOI":"10.1212\/CPJ.0000000000200169","article-title":"Managing antiseizure medications in pregnancy","volume":"13","author":"Freund","year":"2023","journal-title":"Neurol Clin Pract"},{"key":"10.1016\/j.yebeh.2026.111192_b0045","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1212\/01.CON.0000431383.14061.e6","article-title":"Epilepsy, and women\u2019s issues","volume":"19","author":"Pregnancy","year":"2013","journal-title":"CONTINUUM: Lifelong Learn Neurol"},{"issue":"2","key":"10.1016\/j.yebeh.2026.111192_b0050","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/acn3.29","article-title":"Model\u2010based lamotrigine clearance changes during pregnancy: clinical implication","volume":"1","author":"Polepally","year":"2014","journal-title":"Ann Clin Transl Neurol"},{"issue":"1","key":"10.1016\/j.yebeh.2026.111192_b0150","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1586\/17512433.1.1.129","article-title":"Pharmacokinetics of antiepileptic drugs in pregnancy","volume":"1","author":"Sabers","year":"2008","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.yebeh.2026.111192_b0205","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1097\/FTD.0000000000001195","article-title":"Changes in perampanel pharmacokinetics and cytochrome P450 3A4 activity before, during, and after pregnancy","volume":"46","author":"Yamamoto","year":"2024","journal-title":"Ther Drug Monit"},{"issue":"3","key":"10.1016\/j.yebeh.2026.111192_b0055","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/epi.12109","article-title":"Antiepileptic drug treatment in pregnancy: changes in drug disposition and their clinical implications","volume":"54","author":"Tomson","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2026.111192_b0060","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.yebeh.2018.04.009","article-title":"Changes in antiepileptic drug-prescribing patterns in pregnant women with epilepsy","volume":"84","author":"Meador","year":"2018","journal-title":"Epilepsy Behav"},{"issue":"9","key":"10.1016\/j.yebeh.2026.111192_b0065","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000008001","article-title":"Declining malformation rates with changed antiepileptic drug prescribing","volume":"93","author":"Tomson","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2026.111192_b0070","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.eplepsyres.2018.01.011","article-title":"UGT polymorphisms and lamotrigine clearance during pregnancy","volume":"140","author":"Petrenaite","year":"2018","journal-title":"Epilepsy Res"},{"issue":"7","key":"10.1016\/j.yebeh.2026.111192_b0075","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.1315","article-title":"Pharmacokinetic changes and therapeutic drug monitoring of lamotrigine during pregnancy","volume":"9","author":"Ding","year":"2019","journal-title":"Brain Behav"},{"key":"10.1016\/j.yebeh.2026.111192_b0080","doi-asserted-by":"crossref","unstructured":"Pennell PB, Peng L, Newport DJ, et al. Lamotrigine in pregnancy: clearance, therapeutic drug monitoring, and seizure frequency. Neurology. 2008;70(22 Part 2):2130-2136.","DOI":"10.1212\/01.wnl.0000289511.20864.2a"},{"issue":"9","key":"10.1016\/j.yebeh.2026.111192_b0085","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1111\/j.1528-1167.2005.10105.x","article-title":"Ethinyl estradiol, not progestogens, reduces lamotrigine serum concentrations","volume":"46","author":"Reimers","year":"2005","journal-title":"Epilepsia"},{"issue":"3","key":"10.1016\/j.yebeh.2026.111192_b0090","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.eplepsyres.2011.02.002","article-title":"Lamotrigine and its N2-glucuronide during pregnancy: the significance of renal clearance and estradiol","volume":"94","author":"Reimers","year":"2011","journal-title":"Epilepsy Res"},{"issue":"4","key":"10.1016\/j.yebeh.2026.111192_b0095","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1002\/ana.25321","article-title":"Lamotrigine clearance increases by 5 weeks gestational age: relationship to estradiol concentrations and gestational age","volume":"84","author":"Karanam","year":"2018","journal-title":"Ann Neurol"},{"issue":"4","key":"10.1016\/j.yebeh.2026.111192_b0100","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1001\/jamaneurol.2021.5487","article-title":"Antiseizure medication concentrations during pregnancy: results from the maternal outcomes and neurodevelopmental effects of antiepileptic drugs (MONEAD) study","volume":"79","author":"Pennell","year":"2022","journal-title":"JAMA Neurol"},{"issue":"4","key":"10.1016\/j.yebeh.2026.111192_b0105","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1002\/hep.20131","article-title":"Variation of hepatic glucuronidation: Novel functional polymorphisms of the UDP-glucuronosyltransferase UGT1A4","volume":"39","author":"Ehmer","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.yebeh.2026.111192_b0110","doi-asserted-by":"crossref","unstructured":"Vaiva Petrenaite a, , Inger \u00d6hman b, et al. UGT polymorphisms and lamotrigine clearance during pregnancy. doi:10.1016\/j.eplepsyres.2018.01.011.","DOI":"10.1016\/j.eplepsyres.2018.01.011"},{"key":"10.1016\/j.yebeh.2026.111192_b0115","doi-asserted-by":"crossref","unstructured":"Antiseizure Medication Dosing Strategy During Pregnancy and Early Postpartum in Women With Epilepsy in MONEAD. doi: 10.1212\/WNL.0000000000214483.","DOI":"10.1212\/WNL.0000000000214483"},{"issue":"3","key":"10.1016\/j.yebeh.2026.111192_b0120","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/BF00540963","article-title":"Pharmacokinetics of oxcarbazepine and 10-hydroxy-carbazepine in the newborn child of an oxcarbazepine-treated mother","volume":"34","author":"B\u00fclau","year":"1988","journal-title":"Eur J Clin Pharmacol"},{"issue":"12","key":"10.1016\/j.yebeh.2026.111192_b0125","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1111\/j.1528-1167.2010.02771.x","article-title":"Drug monitoring of lamotrigine and oxcarbazepine combination during pregnancy","volume":"51","author":"Wegner","year":"2010","journal-title":"Epilepsia"},{"issue":"8","key":"10.1016\/j.yebeh.2026.111192_b0130","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1212\/01.wnl.0000240047.11166.0e","article-title":"Oxcarbazepine concentrations during pregnancy: a retrospective study in patients with epilepsy","volume":"67","author":"Christensen","year":"2006","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.yebeh.2026.111192_b0135","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1111\/epi.12302","article-title":"Seizure control and treatment changes in pregnancy: observations from the EURAP epilepsy pregnancy registry","volume":"54","author":"Battino","year":"2013","journal-title":"Epilepsia"},{"issue":"2\u20133","key":"10.1016\/j.yebeh.2026.111192_b0140","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.eplepsyres.2009.01.011","article-title":"Seizure deterioration in women treated with oxcarbazepine during pregnancy","volume":"84","author":"Petrenaite","year":"2009","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2026.111192_b0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.pnpbp.2024.111030","article-title":"The impact of pregnancy on the pharmacokinetics of antiseizure medications: a systematic review and meta-analysis of data from 674 pregnancies","volume":"133","author":"Schoretsanitis","year":"2024","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.yebeh.2026.111192_b0155","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.eplepsyres.2018.02.004","article-title":"Pharmacokinetic variability of valproate during pregnancy \u2013 Implications for the use of therapeutic drug monitoring","volume":"141","author":"Johannessen Landmark","year":"2018","journal-title":"Epilepsy Res"},{"issue":"18","key":"10.1016\/j.yebeh.2026.111192_b0160","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1212\/WNL.0000000000003157","article-title":"Cognition in school-age children exposed to levetiracetam, topiramate, or sodium valproate","volume":"87","author":"Bromley","year":"2016","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.yebeh.2026.111192_b0165","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/S1474-4422(12)70323-X","article-title":"Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study","volume":"12","author":"Meador","year":"2013","journal-title":"Lancet Neurol"},{"issue":"21","key":"10.1016\/j.yebeh.2026.111192_b0170","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1212\/WNL.0b013e3182574f39","article-title":"Comparative safety of antiepileptic drugs during pregnancy","volume":"78","author":"Hern\u00e1ndez-D\u00edaz","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2026.111192_b0175","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.yebeh.2014.02.011","article-title":"Carbamazepine clearance and seizure stability during pregnancy","volume":"33","author":"Johnson","year":"2014","journal-title":"Epilepsy Behav"},{"issue":"6 SUPPL. 2","key":"10.1016\/j.yebeh.2026.111192_b0180","first-page":"35","article-title":"Antiepileptic drug pharmacokinetics during pregnancy and lactation","volume":"61","author":"Pennell","year":"2003","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.yebeh.2026.111192_b0185","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1111\/j.0013-9580.2004.12704.x","article-title":"Phenobarbital for the treatment of epilepsy in the 21st century: a critical review","volume":"45","author":"Kwan","year":"2004","journal-title":"Epilepsia"},{"issue":"6","key":"10.1016\/j.yebeh.2026.111192_b0190","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/S1474-4422(18)30107-8","article-title":"Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry","volume":"17","author":"Tomson","year":"2018","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.yebeh.2026.111192_b0195","unstructured":"Landmark CJ. Pharmacokinetic data on brivaracetam, lacosamide and perampanel during pregnancy and lactation."},{"issue":"16_supplement","key":"10.1016\/j.yebeh.2026.111192_b0200","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.88.16_supplement.P3.237","article-title":"Predictions of the pharmacokinetic profile of perampanel during pregnancy using physiologically based pharmacokinetic (PBPK) modeling (P3.237)","volume":"88","author":"Schuck","year":"2017","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.yebeh.2026.111192_b0210","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s10928-020-09711-2","article-title":"Prediction of maternal pharmacokinetics using physiologically based pharmacokinetic models: assessing the impact of the longitudinal changes in the activity of CYP1A2, CYP2D6 and CYP3A4 enzymes during pregnancy","volume":"47","author":"Abduljalil","year":"2020","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"10.1016\/j.yebeh.2026.111192_b0215","doi-asserted-by":"crossref","unstructured":"Maria A. Barbieri, Emilio Perucca, Edoardo Spina, Paola Rota and Valentina Franco. Cenobamate: a review of its pharmacological properties, clinical efficacy and tolerability profile in the treatment of epilepsy. doi: 10.2174\/1871527321666220113110044.","DOI":"10.2174\/1871527321666220113110044"},{"key":"10.1016\/j.yebeh.2026.111192_b0220","unstructured":"Anthony D. Jimenez a, , Isabel Toghramadjian b, et al. Cenobamate and pregnancy: A-single level 4 epilepsy center experience. doi:https:\/\/doi-org.ezproxy.bu.edu\/10.1016\/j.yebeh.2025.110440."},{"key":"10.1016\/j.yebeh.2026.111192_b0225","unstructured":"Tiara Paul a, , Maromi Nei b. Cenobamate use in pregnancy: A case report. doi:https:\/\/doi-org.ezproxy.bu.edu\/10.1016\/j.seizure.2025.05.016."},{"issue":"3","key":"10.1016\/j.yebeh.2026.111192_b0230","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1053\/j.ackd.2013.01.012","article-title":"Renal physiology of pregnancy","volume":"20","author":"Cheung","year":"2013","journal-title":"Adv Chronic Kidney Dis"},{"issue":"5","key":"10.1016\/j.yebeh.2026.111192_b0235","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1111\/epi.17925","article-title":"Therapeutic drug monitoring in pregnancy: Levetiracetam","volume":"65","author":"Fallik","year":"2024","journal-title":"Epilepsia"},{"issue":"6","key":"10.1016\/j.yebeh.2026.111192_b0240","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1111\/j.1528-1167.2007.01032.x","article-title":"Pharmacokinetics of levetiracetam during pregnancy, delivery, in the neonatal period, and lactation","volume":"48","author":"Tomson","year":"2007","journal-title":"Epilepsia"},{"issue":"2","key":"10.1016\/j.yebeh.2026.111192_b0245","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.seizure.2007.11.027","article-title":"Serum concentration\/dose ratio of levetiracetam before, during and after pregnancy","volume":"17","author":"Westin","year":"2008","journal-title":"Seizure"},{"issue":"2","key":"10.1016\/j.yebeh.2026.111192_b0250","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000201348","article-title":"Association of levetiracetam concentration with seizure frequency in pregnant women with epilepsy","volume":"100","author":"Schelhaas","year":"2023","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.yebeh.2026.111192_b0255","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1111\/bcp.15572","article-title":"Population pharmacokinetics and dosing regimen optimization of levetiracetam in epilepsy during pregnancy","volume":"89","author":"Li","year":"2023","journal-title":"Br J Clin Pharmacol"},{"issue":"s1","key":"10.1016\/j.yebeh.2026.111192_b0260","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1528-1157.2000.tb02174.x","article-title":"Clinical pharmacology of topiramate: a review","volume":"41","author":"Garnett","year":"2000","journal-title":"Epilepsia"},{"issue":"3","key":"10.1016\/j.yebeh.2026.111192_b0265","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1111\/j.1528-1167.2008.01776.x","article-title":"Serum concentration\/dose ratio of topiramate during pregnancy","volume":"50","author":"Westin","year":"2009","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2026.111192_b0270","unstructured":"\u00d6hman I, Vitols S, Luef G, S\u00f6derfeldt B, Tomson T. Topiramate Kinetics during Delivery, Lactation, and in the Neonate: Preliminary Observations."},{"issue":"7","key":"10.1016\/j.yebeh.2026.111192_b0275","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1001\/jamaneurol.2022.1269","article-title":"Association of prenatal exposure to antiseizure medication with risk of autism and intellectual disability","volume":"79","author":"Bj\u00f8rk","year":"2022","journal-title":"JAMA Neurol"},{"issue":"2","key":"10.1016\/j.yebeh.2026.111192_b0280","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.yebeh.2013.08.001","article-title":"Fetal antiepileptic drug exposure: adaptive and emotional\/behavioral functioning at age 6years","volume":"29","author":"Cohen","year":"2013","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2026.111192_b0285","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/j.seizure.2004.04.016","article-title":"Zonisamide: chemistry, mechanism of action, and pharmacokinetics","volume":"13","author":"Leppik","year":"2004","journal-title":"Seizure"},{"issue":"3","key":"10.1016\/j.yebeh.2026.111192_b0290","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/j.1528-1167.2007.00983.x","article-title":"Pharmacokinetics and drug interactions with zonisamide","volume":"48","author":"Sills","year":"2007","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2026.111192_b0295","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.eplepsyres.2018.05.002","article-title":"Zonisamide serum concentrations during pregnancy","volume":"144","author":"Reimers","year":"2018","journal-title":"Epilepsy Res"},{"issue":"10","key":"10.1016\/j.yebeh.2026.111192_b0300","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1111\/j.1528-1167.2005.00251.x","article-title":"Pharmacokinetics of gabapentin during delivery, in the neonatal period, and lactation: does a fetal accumulation occur during pregnancy?","volume":"46","author":"\u00d6hman","year":"2005","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2026.111192_b0305","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.seizure.2021.03.011","article-title":"Change in the pharmacokinetics of lacosamide before, during, and after pregnancy","volume":"88","author":"Fukushima","year":"2021","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2026.111192_b0310","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2021.108253","article-title":"Lacosamide serum concentrations during pregnancy","volume":"123","author":"Zutshi","year":"2021","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2026.111192_b0315","doi-asserted-by":"crossref","unstructured":"Prediction of lacosamide concentrations to support dose optimization during pregnancy. doi:doi: 10.1111\/epi.18184.","DOI":"10.1111\/epi.18184"},{"key":"10.1016\/j.yebeh.2026.111192_b0320","first-page":"1","article-title":"A review of the pharmacology and clinical efficacy of brivaracetam","volume":"10","author":"Klein","year":"2018","journal-title":"Clin Pharmacol: Adv Appl"},{"key":"10.1016\/j.yebeh.2026.111192_b0325","unstructured":"Outcomes in three cases after brivaracetam treatment during pregnancy. doi:https:\/\/doi.org\/10.1111\/ane.13222Digital Object Identifier (DOI)."},{"issue":"1","key":"10.1016\/j.yebeh.2026.111192_b0330","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s42466-024-00312-9","article-title":"Brivaracetam and topiramate serum levels during pregnancy and delivery: a case report and a review of literature","volume":"6","author":"Hahn","year":"2024","journal-title":"Neurol Res Pract"},{"key":"10.1016\/j.yebeh.2026.111192_b0335","doi-asserted-by":"crossref","unstructured":"Li D, Franco S, Pennell PB. The impact of pregnancy-related hormonal and physiological changes on antiseizure medications: expert perspective. Expert Rev Clin Pharmacol. Published online May 2024:1-9. doi:10.1080\/17512433.2024.2356617.","DOI":"10.1080\/17512433.2024.2356617"},{"key":"10.1016\/j.yebeh.2026.111192_b0340","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ejogrb.2013.10.021","article-title":"Effects of monitoring strategies on seizures in pregnant women on lamotrigine: a meta-analysis","volume":"172","author":"Pirie","year":"2014","journal-title":"Eur J Obstetr Gynecol Reprod Biol"},{"issue":"26","key":"10.1016\/j.yebeh.2026.111192_b0345","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1056\/NEJMoa2008663","article-title":"Changes in seizure frequency and antiepileptic therapy during pregnancy","volume":"383","author":"Pennell","year":"2020","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.yebeh.2026.111192_b0350","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1002\/phar.2856","article-title":"Empiric dosing strategies to predict lamotrigine concentrations during pregnancy","volume":"43","author":"Barry","year":"2023","journal-title":"Pharmacotherapy"},{"issue":"23","key":"10.1016\/j.yebeh.2026.111192_b0355","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta22230","article-title":"AntiEpileptic drug monitoring in PREgnancy (EMPiRE): a double-blind randomised trial on effectiveness and acceptability of monitoring strategies","volume":"22","author":"Thangaratinam","year":"2018","journal-title":"Health Technol Assess"},{"issue":"4","key":"10.1016\/j.yebeh.2026.111192_b0360","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1212\/WNL.0000000000001182","article-title":"IQ at 6 years after in utero exposure to antiepileptic drugs","volume":"84","author":"Baker","year":"2015","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.yebeh.2026.111192_b0365","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/S1474-4422(23)00199-0","article-title":"Cognitive outcomes at age 3 years in children with fetal exposure to antiseizure medications (MONEAD study) in the USA: a prospective, observational cohort study","volume":"22","author":"Meador","year":"2023","journal-title":"Lancet Neurol"},{"issue":"8","key":"10.1016\/j.yebeh.2026.111192_b0370","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1001\/jamaneurol.2021.1583","article-title":"Two-year-old cognitive outcomes in children of pregnant women with epilepsy in the maternal outcomes and neurodevelopmental effects of antiepileptic drugs study","volume":"78","author":"Meador","year":"2021","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.yebeh.2026.111192_b0375","doi-asserted-by":"crossref","unstructured":"Harden CL, Pennell PB, Koppel BS, et al. Practice Parameter update: Management issues for women with epilepsy\u2014Focus on pregnancy (an evidence-based review): Vitamin K, folic acid, blood levels, and breastfeeding. Neurology. 2009;73(2):142 LP - 149. doi: 10.1212\/WNL.0b013e3181a6b325.","DOI":"10.1212\/WNL.0b013e3181a6b325"},{"issue":"1","key":"10.1016\/j.yebeh.2026.111192_b0380","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1002\/epi4.12086","article-title":"Are doses of lamotrigine or levetiracetam adjusted during pregnancy?","volume":"3","author":"Richards","year":"2018","journal-title":"Epilepsia Open"},{"issue":"1","key":"10.1016\/j.yebeh.2026.111192_b0385","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1001\/jamaneurol.2023.4506","article-title":"When pregnancy becomes an inclusion criterion in neuroscience research","volume":"81","author":"Huynh","year":"2024","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.yebeh.2026.111192_b0390","unstructured":"Irene A\u00edcua-Rap\u00fan, Pascal Andr\u00e9, Andrea O. Rossetti, Laurent A. D\u00e9costerd, Thierry Buclin, Jan Novy. Seizure freedom and plasma levels of newer generation antiseizure medications. doi:https:\/\/doi-org.ezproxy.bu.edu\/10.1111\/ane.13450Digital Object Identifier (DOI)."}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505026003136?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505026003136?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T03:32:42Z","timestamp":1789011162000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505026003136"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":78,"alternative-id":["S1525505026003136"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2026.111192","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimizing epilepsy management and pregnancy outcomes: the role of therapeutic drug monitoring","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2026.111192","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"111192"}}